JPMorgan lowered the firm’s price target on Ardent Health (ARDT) to $15 from $18 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q2 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $23 from $24 at Leerink
- Ardent Health price target lowered to $20 from $24 at KeyBanc
- Sell Rating for Ardent Health Partners Due to Anticipated State Directed Payment Cuts and Profitability Challenges
- Ardent Health Reports Strong Q2 2025 Results
- Ardent Health reports Q2 EPS 52c, consensus 32c